Outcomes of Vogt-Koyanagi-Harada Disease: A Subanalysis From a Randomized Clinical Trial of Antimetabolite Therapies.

ABSTRACT:

Purpose

To report outcomes of Vogt-Koyanagi-Harada (VKH) disease from a clinical trial of antimetabolite therapies.

Design

Subanalysis from an observer-masked randomized clinical trial for noninfectious intermediate, posterior, and panuveitis.

Methods

setting: Clinical practice at Aravind Eye Hospitals, India.

Patient population

Forty-three of 80 patients enrolled (54%) diagnosed with VKH.

Intervention

Patients were randomized to either 25 mg oral methotrexate weekly or 1 g mycophenolate mofetil twice daily, with a corticosteroid taper.

Main outcome measures

Primary outcome was corticosteroid-sparing control of inflammation at 5 and 6 months. Secondary outcomes included visual acuity, central subfield thickness, and adverse events. Patients were c

SUBMITTER: Shen E 

PROVIDER: S-EPMC4969141 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature